Abstract
Butyrate-producing bacteria (BPB) are potential probiotic candidates for inflammatory bowel diseases as they are often depleted in the diseased gut microbiota. However, here we found that augmentation of a human-derived butyrate-producing strain, Anaerostipes hadrus BPB5, significantly aggravated colitis in dextran sulphate sodium (DSS)-treated mice while exerting no detrimental effect in healthy mice. We explored how the interaction between BPB5 and gut microbiota may contribute to this differential impact on the hosts. Butyrate production and severity of colitis were assessed in both healthy and DSS-treated mice, and gut microbiota structural changes were analysed using high-throughput sequencing. BPB5-inoculated healthy mice showed no signs of colitis, but increased butyrate content in the gut. In DSS-treated mice, BPB5 augmentation did not increase butyrate content, but induced significantly more severe disease activity index and much higher mortality. BPB5 didn't induce significant changes of gut microbiota in healthy hosts, but expedited the structural shifts 3 days earlier toward the disease phase in BPB5-augmented than DSS-treated animals. The differential response of gut microbiota in healthy and DSS-treated mice to the same potentially beneficial bacterium with drastically different health consequences suggest that animals with dysbiotic gut microbiota should also be employed for the safety assessment of probiotic candidates.
Introduction
Inflammatory Bowel Diseases (IBDs) are characterized by "dysbiosis"—a microbial imbalance where beneficial bacteria, particularly those that produce the anti-inflammatory metabolite butyrate, are depleted. Consequently, researchers have viewed "re-seeding" the gut with butyrate-producing bacteria (BPB) as a promising therapeutic strategy. However, the safety of these candidates is almost exclusively tested in healthy animal models. This study addresses a critical blind spot: Does a "beneficial" bacterium behave differently when introduced into a gut that is already inflamed or imbalanced? The authors investigate whether the interaction between a new probiotic candidate and an unstable resident microbiota could inadvertently do more harm than good.
Characterization of Anaerostipes hadrus BPB5
The researchers isolated a specific strain, Anaerostipes hadrus BPB5, from a healthy human donor. The strain was characterized using whole-genome sequencing (PacBio and Illumina) to map metabolic pathways and ensure the absence of known virulence factors. Metabolic profiling via gas chromatography confirmed its ability to produce butyrate from various carbon sources.
Phylogenetic analysis placed BPB5 within the Lachnospiraceae family, a group well-known for butyrate production. The complete genome was submitted to NCBI (Accession: CP012098).
Experimental Results
The study tested BPB5 in three groups: healthy specific-pathogen-free (SPF) mice, germ-free mice, and mice with Dextran Sulphate Sodium (DSS)-induced colitis.
The Context Dependency of "Good" Bacteria
In healthy mice, BPB5 acted as expected, increasing butyrate levels without causing inflammation or significant structural changes to the microbiome. However, in the colitis model, it became a "biological accelerant." In the DSS-induced colitis group, adding BPB5 led to significantly higher mortality (5 out of 12 mice died, compared to only 1 in the DSS-only group). It also caused significantly higher Disease Activity Index (DAI) scores and shorter colon lengths.
Accelerated Dysbiosis
Microbiome analysis using 16S rRNA sequencing and Principal Coordinate Analysis (PCoA) revealed that BPB5 pushed the gut microbiota toward a "disease phase" roughly three days earlier than in mice treated with DSS alone. BPB5 appeared to trigger an "explosion" of indigenous opportunistic bacteria, showing a positive correlation with an earlier rise in Akkermansia and Parasutterella species. While Akkermansia is often considered beneficial in metabolic health, this study suggests it may play a pro-inflammatory role in acute colitis.
The Butyrate Paradox
Despite being a butyrate producer, BPB5 supplementation did not increase butyrate levels in the diseased mice. This is likely because the overall collapse of the microbial community overrode the contribution of the single strain. Furthermore, mice receiving BPB5 had higher levels of Serum Lipopolysaccharide Binding Protein (LBP), indicating a higher burden of bacteria-derived antigens entering the bloodstream.
Discussion and Conclusion
This study reveals that "safety" is not an intrinsic property of a microbe but an emergent property of the microbe-host-microbiota interaction. BPB5 functions as a catalyst that accelerates the collapse of the gut microbiome’s healthy structure in a diseased context.
While the study identified which bacteria shifted, the exact molecular mechanism remains unclear. It is unknown if BPB5 outcompetes other beneficial bugs for nutrients or if it produces signaling molecules that favor opportunistic pathogens in an inflamed environment. The findings suggest a paradigm shift in probiotic safety assessment: candidates intended for therapeutic use in diseased states must be tested in dysbiotic models, not just healthy ones. Future work should investigate whether other common probiotic strains exhibit similar context-dependent behavior.
Summary updated